Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Septimeb in hospitalized adults with COVID-19
IRCT20100601004076N27Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of Septimeb in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Patients' Mortality. Started Jan 2022; status: completed.
02
Drugs
Septimeb
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20100601004076N27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100601004076N27.